NEW YORK--(BUSINESS WIRE)--Aug. 25, 2005--(Investrend Research Syndicate) A research note on MIV Technologies, Inc. (OTCBB: MIVT) has been issued by Investrend Research Affiliate Beacon Equity...
#26: MIVT News MIVT Receives Prestigious Frost & Sullivan 2005 Award for Technology Innovation in Field of Medical Coatings; Biocompatible Coating Pioneer Recognized for Development of Visionary Hydroxyapatite (HAp) Coating Technologies
VANCOUVER, British Columbia--(BUSINESS WIRE)--Aug. 24, 2005--MIV Therapeutics, Inc. (OTCBB:MIVT), a developer of next-generation biocompatible passive and drug-eluting stent coatings and drug...
Redaktion Wirtschaft/Gesundheit/Medizin VANCOUVER, British Columbia--(BUSINESS WIRE)-24. Aug. 2005--MIV Therapeutics, Inc. (OTCBB:MIVT), ein Entwickler biokompatibler passiver und...
VANCOUVER, British Columbia--(BUSINESS WIRE)--Aug. 22, 2005--MIV Therapeutics, Inc. (OTCBB: MIVT), a developer of next-generation biocompatible stent coatings and drug delivery technologies for...
Redaktion Wirtschaft/Gesundheit/Medizin VANCOUVER, British Columbia--(BUSINESS WIRE)-22. Aug. 2005--MIV Therapeutics, Inc. (OTCBB: MIVT), ein Entwickler von biokompatiblen Stentbeschichtungen und...
#23: MIVT News MIV Therapeutics' Breakthrough Technology Praised in Independent Research Service by Frost & Sullivan; Prestigious Growth Consulting Company Extols Company's Unique Biocompatible HAp Technology for Medical Coatings and Drug Delivery Sectors
VANCOUVER, British Columbia--(BUSINESS WIRE)--Aug. 17, 2005--MIV Therapeutics, Inc. (OTCBB: MIVT), a developer of next-generation biocompatible and drug-delivery coatings for cardiovascular stents,...
#22: MIVT News MIV Therapeutics Special Advisor on Scientific and International Affairs Named Secretary General of World Hypertension League; Dr. Arun Chockalingam to Assume Leadership Role in Pre-eminent Global Health Care Organization
VANCOUVER, British Columbia--(BUSINESS WIRE)--July 26, 2005--MIV Therapeutics, Inc. (OTCBB: MIVT), a developer of next-generation biocompatible stent coatings and drug delivery technologies for the...
MIV Therapeutics Announces Availability of Research Report Projecting 300% Share Value Increase in 12 Months; Report by SISM Research & Investment Services Affirms 'Speculative Buy' Recommendation...
#19: MIVT News Research MIV Therapeutics CEO Alan Lindsay Outlines Advanced Stent-Coating Technologies in Interview with PRBroadcast.com; CEO Outlines Acquisitions and other Milestones as Company Develops Biocompatible and Drug-Eluting Coatings
MIV Therapeutics CEO Alan Lindsay Outlines Advanced Stent-Coating Technologies in Interview with PRBroadcast.com; CEO Outlines Acquisitions and other Milestones as Company Develops Biocompatible...
MIV Therapeutics Announces Online Availability of Corporate Video Reporting on Company's Biocompatible Coatings
VANCOUVER, British Columbia
MIV Therapeutics Inc.
Investors:
Dan Savino,...
#17: MIVT MIV Therapeutics Announces Availability of Online Audio Interview with CEO Alan Lindsay on CEOcast.com; CEO Discusses the Company's Business and Development Strategy in Advanced Drug-Eluting Stent Sector
MIV Therapeutics Announces Availability of Online Audio Interview with CEO Alan Lindsay on CEOcast.com; CEO Discusses the Company's Business and Development Strategy in Advanced Drug-Eluting Stent...
MIV Therapeutics Announces Excellent Results in Animal Studies of New Multilayer Drug-Eluting Coating for Cardiovascular Stents
VANCOUVER, British Columbia
MIV Therapeutics Inc.
Investors:
...
#15: MIVT MIV Therapeutics Chief Medical Officer to Discuss Advanced Drug-Eluting Stent Coating at Third Annual Biotechnology Conference; MIVT's Dr. Dov Shimon to Discuss Company's Proprietary Biocompatible Medical Device Coating Technology at New York Event
MIV Therapeutics Chief Medical Officer to Discuss Advanced Drug-Eluting Stent Coating at Third Annual Biotechnology Conference; MIVT's Dr. Dov Shimon to Discuss Company's Proprietary Biocompatible...
MIV Therapeutics Reports Successful Progress of Animal Studies on Proprietary Hydroxyapatite Coatings for Coronary Stents
VANCOUVER, British Columbia
MIV Therapeutics Inc.
Investors:
Dan...
